HJBC/iStock Editorial via Getty Images
- Shares of Denali Therapeutics (NASDAQ:DNLI) opened lower on Friday after the company said its partner Sanofi (NASDAQ:SNY) has faced a setback in a mid-stage trial for a jointly developed neurology candidate called SAR443820 (DNL788).
- Denali Therapeutics stock fell as Sanofi announced that the Phase 2 trial named HIMALAYA did not meet the main goal in patients with the rare neurological disease, amyotrophic lateral sclerosis (ALS).
- Sanofi stated that SAR443820 (DNL788), an oral RIPK1 Inhibitor, did not achieve the primary endpoint of change in a clinical measure called the ALS Functional Rating Scale-Revised (ALSFRS-R) in the trial.
- Although the therapy missed the mark in ALS, Sanofi plans to advance it in another Phase 2 trial for multiple sclerosis, an immune-mediated neurological condition.
- SAR443820 (DNL788) is undergoing two mid-stage clinical trials for ALS and MS as part of a 2018 collaboration agreement between the two companies.
